Baird Maintains a 'Neutral' on Amylin Pharmaceuticals (AMLN); Q3-11: Continued Revenue Stabilization and a New Indication for Byetta
Go back to Baird Maintains a 'Neutral' on Amylin Pharmaceuticals (AMLN); Q3-11: Continued Revenue Stabilization and a New Indication for Byetta| Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) | Delayed: 30.98 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $30.98 | 52 Week High | $31.02 | |||
| Open | $3.30 | 52 Week Low | $8.03 | |||
| Day High | $30.98 | P/E | N/A | |||
| Day Low | $30.98 | EPS | $-4.38 | |||
| Volume | 440,704 | |||||
